Biomarkers such as PD-L1 expression on tumor and immune cells, tumor mutational burden (TMB), and microsatellite instability (MSI) are used in clinical practice to identify patients with various malignancies likely to respond to ICIs5–7. The gene discussed is CD274; the disease is neoplasm.